Presented by Ruiben Feng, PhD, Executive Director, Neurobiology and Neuropharmacology at Shanghai ChemPartner.
Abstract:
EEG analysis (Electroencephalography) is becoming a promising translatable biomarker for predicting the likelihood that novel therapies and compounds will exhibit clinical efficacy early in preclinical development. EEG and relevant analyses have been very useful in the drug development process in the context of several major central nervous system (CNS) diseases including Alzheimer’s disease, epilepsy, sleep/wake disorders, schizophrenia, depression, attention deficit, hyperactivity disorder, and pain. Additionally, EEG-based signatures represent promising preclinical screens to quickly determine CNS penetration, drug-target engagement, evidence of efficacy, pharmacokinetic/pharmacodynamic profile, CNS safety and toxicity, and pro-convulsant risk.
In this webinar, the featured speaker will review the EEG analysis, related optimization parameters, and candidate compound selection as well as case studies where EEG-based signatures in correlation with animal behavior could validate the EEG as the endpoint for a set of translatable biomarkers bridging preclinical and clinical programs.
Join this webinar to gain insights into EEG analysis as physiological endpoints to facilitate drug discovery for CNS diseases.
